PMID- 29785089
OWN - NLM
STAT- MEDLINE
DCOM- 20181011
LR  - 20240314
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 12
DP  - 2018
TI  - Schisandrin B ameliorated chondrocytes inflammation and osteoarthritis via 
      suppression of NF-kappaB and MAPK signal pathways.
PG  - 1195-1204
LID - 10.2147/DDDT.S162014 [doi]
AB  - INTRODUCTION: Osteoarthritis (OA) is the most prevalent joint disorder in the 
      elderly population, and inflammatory mediators like IL-1beta were thought to play 
      central roles in its development. Schisandrin B, the main active component 
      derived from Schisandra chinensis, exhibited anti-oxidative and antiinflammatory 
      properties. METHODS: In the present study, the protective effect and the 
      underlying mechanism of Schisan-drin B on OA was investigated in vivo and in 
      vitro. RESULTS: The results showed that Schisandrin B decreased IL-1beta-induced 
      upregulation of matrix metalloproteinase 3 (MMP3), MMP13, IL-6, and inducible 
      nitric oxide synthase (iNOS) and increased IL-1beta-induced downregulation of 
      collagen II, aggrecan, and sox9 as well. Schisandrin B significantly decreased 
      IL-1beta-induced p65 phosphorylation and nuclear translocation of p65 in rat 
      chondrocytes. Mitogen-activated protein kinase (MAPK) activation was also 
      inhibited by Schisandrin B, as evidenced by the reduction of p38, extracellular 
      signal-regulated kinase (Erk), and c-Jun amino-terminal kinase (Jnk) 
      phosphorylation. In addition, Schisandrin B prevented cartilage degeneration in 
      rat OA model with significantly lower Mankin's score than the control group. 
      CONCLUSION: Our study demonstrated that Schisandrin B ameliorated chondrocytes 
      inflammation and OA via suppression of nuclear factor-kappaB (NF-kappaB) and MAPK signal 
      pathways, indicating a therapeutic potential in OA treatment.
FAU - Ran, Jisheng
AU  - Ran J
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Ma, Chiyuan
AU  - Ma C
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Xu, Kai
AU  - Xu K
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Xu, Langhai
AU  - Xu L
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - He, Yuzhe
AU  - He Y
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Moqbel, Safwat Adel Abdo
AU  - Moqbel SAA
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Hu, Pengfei
AU  - Hu P
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Jiang, Lifeng
AU  - Jiang L
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Chen, Weiping
AU  - Chen W
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Bao, Jiapeng
AU  - Bao J
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Xiong, Yan
AU  - Xiong Y
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Wu, Lidong
AU  - Wu L
AD  - Department of Orthopedic Surgery, The Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20180509
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Cyclooctanes)
RN  - 0 (Lignans)
RN  - 0 (NF-kappa B)
RN  - 0 (Polycyclic Compounds)
RN  - 02XA4X3KZW (schizandrin B)
RN  - EC 3.4.24.- (Matrix Metalloproteinases)
SB  - IM
MH  - Animals
MH  - Anti-Inflammatory Agents/administration & dosage/pharmacology
MH  - Cell Survival/drug effects
MH  - Cells, Cultured
MH  - Chondrocytes/*drug effects/metabolism
MH  - Cyclooctanes/administration & dosage/pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Inflammation/*drug therapy/metabolism
MH  - Lignans/administration & dosage/*pharmacology
MH  - MAP Kinase Signaling System/*drug effects
MH  - Matrix Metalloproteinases/*metabolism
MH  - NF-kappa B/*antagonists & inhibitors/metabolism
MH  - Osteoarthritis/*drug therapy/metabolism
MH  - Polycyclic Compounds/administration & dosage/*pharmacology
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Schisandra/chemistry
MH  - Structure-Activity Relationship
PMC - PMC5953308
OTO - NOTNLM
OT  - MAPK pathway
OT  - MMPs
OT  - NF-kappaB pathway
OT  - Schisandrin B
OT  - chondrocytes
OT  - osteoarthritis
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2018/05/23 06:00
MHDA- 2018/10/12 06:00
PMCR- 2018/05/09
CRDT- 2018/05/23 06:00
PHST- 2018/05/23 06:00 [entrez]
PHST- 2018/05/23 06:00 [pubmed]
PHST- 2018/10/12 06:00 [medline]
PHST- 2018/05/09 00:00 [pmc-release]
AID - dddt-12-1195 [pii]
AID - 10.2147/DDDT.S162014 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2018 May 9;12:1195-1204. doi: 10.2147/DDDT.S162014. 
      eCollection 2018.